Refine by
Elacestrant Cancer A Case Study Equipment & Supplies
1 equipment items found
Manufactured by:The Menarini Group based inFlorence, ITALY
Elacestrant is a selective estrogen receptor degrader (SERD) evaluated for potential use as a once daily oral treatment in patients with estrogen receptor positive (ER+)/HER2- advanced or metastatic breast cancer. Studies completed to date, including the positive results from the EMERALD phase 3 trial, indicate that the compound has the potential for use as a single agent or in combination with ...